Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,060 Mln
P/E Ratio
198.65
P/B Ratio
6.82
Industry P/E
--
Debt to Equity
0.34
ROE
0.04 %
ROCE
2.94 %
Div. Yield
0 %
Book Value
5.59
EPS
0.2
CFO
$20.18 Mln
EBITDA
$-106.45 Mln
Net Profit
$-113.66 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vericel (VCEL)
| -29.45 | -15.91 | -35.13 | -15.87 | 6.59 | 22.70 | 27.47 |
|
BSE Sensex*
| 2.53 | 3.64 | 5.70 | 8.81 | 11.73 | 20.10 | 11.34 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Vericel (VCEL)
| 53.65 | 35.19 | -32.98 | 27.27 | 77.47 | 0.00 | 217.25 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.89 | 6,904.81 | -- | 38.11 | |
| 70.95 | 7,574.08 | 58.3 | 23.56 | |
| 59.52 | 11,448.88 | 394.4 | 0.76 | |
| 8.25 | 9,704.70 | -- | -3.24 |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North... America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Address: 64 Sidney Street, Cambridge, MA, United States, 02139 Read more
CEO, President & Director
Mr. Dominick C. Colangelo Esq.
CEO, President & Director
Mr. Dominick C. Colangelo Esq.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vericel Corporation (VCEL) stood at $ 433 Mln as on 31-Dec-24
The share price of Vericel Corporation (VCEL) is $38.74 (NASDAQ) as of 28-Apr-2025 16:01 EDT. Vericel Corporation (VCEL) has given a return of 6.59% in the last 3 years.
Vericel Corporation (VCEL) has a market capitalisation of $ 2,060 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Vericel Corporation (VCEL) is 198.65 times as on 28-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vericel Corporation (VCEL) and enter the required number of quantities and click on buy to purchase the shares of Vericel Corporation (VCEL).
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Address: 64 Sidney Street, Cambridge, MA, United States, 02139
The CEO & director of Mr. Dominick C. Colangelo Esq.. is Vericel Corporation (VCEL), and CFO & Sr. VP is Mr. Dominick C. Colangelo Esq..
There is no promoter pledging in Vericel Corporation (VCEL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Vericel Corporation (VCEL) | Ratios |
|---|---|
|
Return on equity(%)
|
4
|
|
Operating margin(%)
|
4.69
|
|
Net Margin(%)
|
4.37
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vericel Corporation (VCEL) was $0 Mln.
$-0.99
(
